While BRCA1 and BRCA2 account for the majority of HRR mutations found in ovarian and breast cancer, deleterious mutations in other non-BRCA HRR genes are found in most cancer types and have been shown to confer sensitivity to PARP inhibitors (21–26). This evidence concerns the gene BRCA1 and cancer.